Novo Nordisk Foundation

Regenerative Medicine Catalyst Grants 2026

Up to DKK 5M (standard) / Up to DKK 10M (collaborative); total pool DKK 100M| Deadline: 1 September 2026 (46 days)|Up to 3 years

Two-phase process: Phase I concept note, then invited Phase II full application. No deadline date stated on page.

Last verified: 24 June 2026

Is this grant right for you? Check your personalised match score. 30s, no email. See my matches →

The Novo Nordisk Foundation Regenerative Medicine Catalyst Grants award up to DKK 5 million (DKK 10 million for collaborative projects) over three years to fund translational and applied regenerative medicine research in Nordic institutions. The call targets established investigators at universities, hospitals, or non-profit research organisations in Denmark, Sweden, Norway, Finland, Iceland, Greenland, and the Faroe Islands, with a focus on stem cell-based therapies and technologies at TRL 3-6. This is a one-off call with a two-phase application process (concept note followed by invited full application) and a total funding pool of DKK 100 million.

Details

Funder	Novo Nordisk Foundation
Budget	Up to DKK 5M (standard) / Up to DKK 10M (collaborative); total pool DKK 100M
Deadline	1 September 2026
Duration	Up to 3 years
Consortium	Optional — collaborative projects require at least 1 international co-applicant from a different country than the main applicant
Application	2-stage: Phase I concept note (internal triage) → Phase II full application (external peer review)
TRL	3-6
Frequency	One-off
Eligible countries	DKSENOFIISGLFO

Eligibility & scope

Main applicant must be an established investigator with primary employment at a university, hospital, or non-profit research institution in a Nordic country (Denmark, Sweden, Norway, Finland, Iceland, Greenland, Faroe Islands). Translational/applied focus on regenerative medicine (stem cell-based therapies); fundamental discovery, adult immune cell (CAR-T/NK), and gene therapy projects are out of scope. For-profit partners may collaborate but cannot receive direct funding (subcontractors excepted).

Who Should Apply

•Established investigators with primary employment at Nordic universities, hospitals, or non-profit research institutions
•Teams pursuing translational/applied regenerative medicine projects, especially stem cell-based therapies
•Researchers working at TRL 3-6 (preclinical to early clinical translation)
•Collaborative consortia with at least one international co-applicant from outside the main applicant's country
•Applicants whose projects exclude fundamental discovery, adult immune cell therapies (CAR-T/NK), and gene therapy

Key Dates

•Phase I deadline: 1 September 2026 (concept note submission)
•Two-stage process: Phase I concept note (internal triage) followed by Phase II full application (external peer review for invited teams)
•Up to three-year project duration

Tips for Applicants

✓The concept note is your gateway, clarity on translational pathway and clinical unmet need will distinguish competitive submissions from those rejected at Phase I triage.
✓For collaborative projects, secure your international co-applicant early; at least one must be from a different Nordic or eligible country and the collaboration must add scientific value, not just tick the consortium box.
✓Position your project at TRL 3-6 explicitly; proposals too early-stage (fundamental discovery, CAR-T/NK development) or too late (late-phase clinical) fall outside scope.

Frequently Asked Questions

How much can I request in a Novo Nordisk Regenerative Medicine Catalyst Grant?

Up to DKK 5 million for a single-applicant project, or up to DKK 10 million for a collaborative project with at least one international co-applicant. The total funding pool is DKK 100 million.

Who is eligible to apply for the Novo Nordisk Regenerative Medicine Catalyst Grant?

Established investigators with primary employment at a university, hospital, or non-profit research institution in Denmark, Sweden, Norway, Finland, Iceland, Greenland, or the Faroe Islands.

What research areas are in scope?

Translational and applied regenerative medicine projects, particularly stem cell-based therapies at TRL 3-6. Fundamental discovery, CAR-T/NK cell therapies, and gene therapy are excluded.

Is collaboration required?

No, single-applicant projects are eligible and receive up to DKK 5 million. Collaborative projects with an international co-applicant from a different country may request up to DKK 10 million.

What is the application timeline?

The call uses a two-phase process: Phase I concept note (deadline 1 September 2026) followed by Phase II full application for invited teams. Peer review occurs at Phase II.

regenerative-medicinestem-cell-therapynovo-nordisk-foundationtranslational-researchnordicestablished-investigatortrl-3-6

View full call →

Share ✉ Email X LinkedIn WhatsApp

Summary generated by AI based on published grant information. Always verify details on the funder's website.